Sofinnova Partners backs Hookipa Biotech

Forbion Capital Partners has participated in the round as a co-investor. Following the investment Hookipa will launch the pre-clinical development and a phase-I proof-of-concept study to further industrialise and validate its Vaxwave technology.

The investor was convinced by the company's technology as it addresses some of the industry's current shortcomings and has the potential to pave the way for the treatment of numerous persistent viral infections.

Sofinnova is currently investing from its €260m Sofinnova Capital VI fund, launched in May 2008.

Company
Hookipa, based in Vienna, is a developer of the proprietary technology platform Vaxwave, specialised in genetic vaccines for the prophylactic and therapeutic treatment of viral diseases. Its latest product represents a new approach to vaccination by providing long-lasting and potent stimulation of both cellular and humoral immunity. Hookipa was founded in July 2011 and is looking to expand its team from the current two people to between 10-15 in the next 12 months.

People
Graziano Seghezzi worked on the transaction for Sofinnova and Sander van Deventer is general partner at Forbion.

Advisers
Equity - PHH Rechtsanwälte, Stephan Prochaska (Legal)

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Austria
• Sofinnova Partners